komet-008: a phase i trial of ziftomenib combinations in kmt2a-rearranged or npm1-mutant aml
Published 7 months ago • 142 plays • Length 2:51Download video MP4
Download video MP3
Similar videos
-
5:00
canto ii - startup
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
3:51
assessing high-risk aml
-
1:24
conventional approaches for all targeted therapies in allo-hsct
-
1:42
aml: new targeted inhibitors as single agents?
-
11:13
capture demo video
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
0:38
optimal time for allo-hsct in aml
-
![[online seminar] dr. kevin chan - key elements of pentacam® axl for myopia management, 09 june 2021](https://i.ytimg.com/vi/ggytvk4q1vs/mqdefault.jpg)
54:33
[online seminar] dr. kevin chan - key elements of pentacam® axl for myopia management, 09 june 2021
-
32:56
echo analyzer monthly maintenance
-
21:54
prof. thomas kohnen, m.d. – pentacam® axl wave – studies and clinical cases
-
5:36
venetoclax and azacitidine in mds patients
-
1:21
intensive therapy of older aml
-
6:19
harnessing apoptosis in aml
-
3:10
novel aml treament approaches
-
2:14
update on the aml treatment landscape
-
3:52
venetoclax & aml
-
4:22
the role of mrd in aml
-
2:41
onvansertib and decitabine in relapsed/refractory aml
-
0:59
idh inhibitors in aml
-
5:18
update on imgn632: cd123 antibody-drug conjugate for r/r aml and bpdcn